Mounjaro cost in Manitoba.

Direct answer

In Manitoba, cash-pay Mounjaro KwikPens are priced off Lilly’s submitted list of about C$300 (2.5 / 5 mg), C$420 (7.5 / 10 mg), and C$540 (12.5 / 15 mg) per ~4-week pen, plus pharmacy markup and dispensing — illustrative counter quotes run roughly C$320–$650+. As of 12 October 2026, Mounjaro is not listed on the Manitoba Drug Benefits Formulary and has no published EDS criteria (unlike Ozempic). Zepbound is the separately authorized tirzepatide brand for weight management; coverage is private-plan or cash.

Illustrative retail cash prices (Winnipeg, Brandon, Thompson)

Mounjaro in Canada is mostly dispensed as a multi-dose KwikPen (four weekly doses per pen). The anchor is the manufacturer’s submitted price published by Canada’s Drug Agency (CDA-AMC) in its 2026 Mounjaro review and reflected in Lilly’s late-2025 Canadian list-price cut; what you pay at the counter adds pharmacy markup and a dispensing fee. Illustrative bands below blend that list price with 2026 reported Canadian pharmacy quotes. Confirm before you fill:

• Winnipeg big-box: warehouse and big-box pharmacies are often toward the lower end of a band when stocked; call with the DIN and ask for the all-in cash price.
• Full-service chains: Shoppers, Rexall, and grocery pharmacies can run higher once markup and dispensing are included.
• Brandon / Thompson / smaller centres: similar bands, fewer quotes to compare — still worth calling two pharmacies, and ask about cold-chain hold if you travel into Winnipeg for a fill.
• Quotes vary widely: some Canadian guides still cite higher bands (around C$405–$750 by dose). If your quote is far above list, ask the pharmacy what is included before you assume that’s the going rate.
• No generic tirzepatide: every tirzepatide product in Health Canada’s Drug Product Database is a Lilly brand (Mounjaro or Zepbound). Authorized generic semaglutide is a different molecule — molecule choice is a clinician decision; see semaglutide vs tirzepatide in Canada.

These are illustrative ranges, not guaranteed quotes. Never invent a co-pay from this page — your private plan’s prior authorization, deductible, and co-insurance rules decide out-of-pocket when coverage applies.

Manitoba Pharmacare / EDS reality (verify the live formulary)

Manitoba government drug benefits follow the Manitoba Drug Benefits Formulary (Part 1 and Part 2) and, for some products, published Exception Drug Status (EDS) criteria. When we reviewed the formulary PDF effective October 1, 2026 and the EDS notice updated the same date on 12 October 2026, no tirzepatide product (Mounjaro or Zepbound) appeared — while Ozempic / listed semaglutide DINs carry published type 2 diabetes EDS wording (see our Ozempic Manitoba Pharmacare EDS guide).

• Not Part 1 / Part 2: drugs not listed there are not routine Pharmacare benefits. An individual EDS request may be considered for an unlisted drug, but Manitoba’s published EDS materials do not currently include a tirzepatide criteria sheet the way they do for Ozempic.
• Contrast with Ozempic: published EDS framing for Ozempic is type 2 diabetes after diet and exercise plus dual therapy with metformin and a sulfonylurea. That pathway does not automatically transfer to Mounjaro.
• MEPP does not create a Mounjaro shortcut: Manitoba Enhanced Pharmacare moved many diabetes medications to no-deductible coverage, but Ozempic itself stayed EDS under traditional Pharmacare — and tirzepatide is not on that published EDS list either.
• Canada’s Drug Agency issued a 2026 recommendation that public plans reimburse Mounjaro for adults with type 2 diabetes (with metformin-based combinations) only with conditions — including price reductions. That is a national recommendation, not a Manitoba listing. Price negotiation through the pan-Canadian Pharmaceutical Alliance and a Manitoba decision would still need to happen, and may not.

Treat every “not covered” statement as time-stamped. Manitoba posts bulletin and formulary updates (Bulletin #151 dated October 1, 2026 at this writing) — re-check before you budget. Official EDS notes: Exception Drug Status (EDS) — Province of Manitoba (PDF).

Private / employer plans in Manitoba

For most working Manitobans, tirzepatide coverage — if any — comes through an employer or individual plan (Blue Cross, Canada Life, Manulife, Sun Life, and others). Manufacturer marketing that “most private plans cover Mounjaro” is a general claim, not a statement about your plan. We cannot invent your co-pay.

• Mounjaro (type 2 diabetes): many plans require prior / special authorization and may police the diagnosis. Ask HR or the insurer for the actual form and whether tirzepatide DINs are listed, carved out, or capped.
• Zepbound (weight management): coverage only if your plan design includes weight-management drugs. Many employer plans exclude that category entirely. BMI, comorbidity, and prior-therapy documentation are common request fields when a form exists.
• Manitoba’s EDS notes say some private insurers require EDS approval before they will cover any part of a prescription cost — for drugs that have an EDS pathway. That gate does not create a published Mounjaro EDS benefit where none is listed.
• A prescription does not equal plan approval, and a denied claim may need a documented resubmission with complete history.
• Lilly’s official Canadian savings programs (mymounjaro and myzepbound) may reduce out-of-pocket for some cash-pay or privately insured patients. Eligibility, exclusions, and stacking rules are program-specific — verify on the official sites.

Zepbound vs Mounjaro in Manitoba (clearing up the confusion)

Search “Zepbound Manitoba” and you’ll hit U.S. pages, U.S. prices, and forum posts saying Zepbound “isn’t in Canada.” Here’s what Health Canada’s own records show:

• Zepbound is authorized and marketed in Canada. Health Canada issued its Notice of Compliance in May 2025, and the Drug Product Database lists six Zepbound KwikPen strengths (2.5 mg to 15 mg) with status “Marketed” (first marketed July 2025).
• Same molecule, different authorization. Mounjaro is authorized to improve glycemic control in adults with type 2 diabetes. Zepbound is authorized for chronic weight management, alongside a reduced-calorie diet and increased physical activity, in adults with a BMI of 30 or more, or 27 to under 30 with at least one weight-related condition (Zepbound product monograph). Using Mounjaro for weight management alone is off-label — a clinician decision, and a common reason private claims get questioned.
• Not to be combined. The Zepbound monograph says it should not be used together with other tirzepatide products (such as Mounjaro) or any GLP-1 receptor agonist.
• Similar list prices. Lilly’s submitted Canadian list prices for Zepbound KwikPens match Mounjaro’s tiers (about C$300 / C$420 / C$540 per pen by dose).
• Public coverage: not on the Manitoba Formulary / published EDS list as of 12 October 2026. CDA-AMC’s 2026 Zepbound review recommended public reimbursement only for a narrow group — adults with a BMI of 27 or more and prediabetes plus at least one unsuccessful dietary attempt. That is a recommendation, not Manitoba coverage.
• U.S. programs don’t apply. U.S. self-pay offers, vials, and U.S.-dollar pricing are not available at Manitoba pharmacies. Cross-border “Zepbound” sellers are a counterfeit risk, not a shortcut.

Three scenarios

Scenario A — Winnipeg resident, type 2 diabetes, no private drug benefits. Expect full cash-pay at illustrative retail (~C$320–$650+ per pen by dose) plus dispensing. Public Pharmacare help for Mounjaro is not listed today. Ask your clinician whether a Health Canada–authorized option that does have published EDS criteria (such as Ozempic when criteria fit) is clinically appropriate — that’s a medical decision, not a cost hack we can recommend from here. See Ozempic Manitoba Pharmacare EDS.

Scenario B — Brandon resident, employer plan with prior auth approved for Mounjaro. After approval, claims may adjudicate at plan percentage / deductible rules rather than full retail. Out-of-pocket remains plan-specific. Keep renewal dates on a calendar if authorization is time-limited.

Scenario C — Thompson or rural MB resident, weight management, no diabetes, asking for “Mounjaro.” Expect the conversation to land on Zepbound (the weight-management authorization) or another option your clinician chooses — and on private coverage or cash. Don’t expect Manitoba Pharmacare EDS to behave like an Ozempic diabetes coupon. Compare Manitoba-serving clinics in our provider directory for visit and partner-pharmacy pricing — prescription not guaranteed, individual results vary. Telehealth may matter more when the nearest walk-in is a long drive.

Legit ways to save (not imports)

1. Pharmacy shop. Call Winnipeg, Brandon, or Thompson pharmacies with the DIN and ask for today’s all-in cash price. Gaps of tens of dollars per pen are common.
2. Official manufacturer savings card. Check Lilly Canada’s mymounjaro / myzepbound programs. Avoid third-party “coupon” sites that push gray-market product.
3. Multi-pen fills. Once dose-stable, ask whether a multi-pen dispense is clinically appropriate — one dispensing fee instead of several.
4. Prior-authorization diligence. If a private claim denies, ask which criteria were missing; incomplete diagnosis, BMI, comorbidity, or prior-therapy history is a frequent fixable failure.
5. Keep receipts. Prescription drugs are generally eligible medical expenses for the medical expense tax credit — confirm with your tax preparer. Pharmacare deductibles and timing also matter mid-year.
6. Telehealth + partner pharmacy pricing. Some Manitoba-serving clinics in our provider directory may quote below local retail through a partner pharmacy — compare, don’t assume.

What you should not do: buy “Mounjaro,” “Zepbound,” “tirzepatide,” or research-use vials from gray-market or overseas sellers, or compounded knock-offs. Counterfeit and contaminated products have been documented in international shipments, and there is no legitimate Canadian shortcut around authorized pharmacy channels. See research-use-only peptides — the Canadian truth.

FAQ

How much does Mounjaro cost in Winnipeg or Brandon?

Lilly’s submitted Canadian list prices are about C$300 per 2.5 mg or 5 mg KwikPen, C$420 per 7.5 mg or 10 mg, and C$540 per 12.5 mg or 15 mg (one pen is about a 4-week supply). Pharmacies add markup and dispensing fees, so illustrative 2026 counter quotes often run roughly C$320–$370, C$450–$510, and C$580–$650+ respectively. Call Winnipeg or Brandon pharmacies with the DIN — these are not personal quotes.

Does Manitoba Pharmacare or EDS cover Mounjaro?

As of 12 October 2026, Mounjaro (tirzepatide) does not appear on the Manitoba Drug Benefits Formulary (Part 1 or Part 2, effective October 1, 2026), and the published Exception Drug Status (EDS) criteria list that names Ozempic / semaglutide does not include tirzepatide. Unlisted drugs may sometimes be considered under individual EDS applications, but there is no published tirzepatide criteria sheet — do not budget as if public coverage is routine. Re-check the live formulary and EDS materials before you assume coverage.

Is Zepbound available in Manitoba, and is it different from Mounjaro?

Yes. Zepbound is Eli Lilly’s Health Canada–authorized tirzepatide brand for chronic weight management, and Health Canada’s Drug Product Database lists six Zepbound KwikPen strengths as marketed. Mounjaro is the same molecule authorized for type 2 diabetes. They have different DINs and indications, should not be used together, and private plans often treat them differently. Neither appears on Manitoba’s public formulary or published EDS list as of this writing. Your clinician decides which, if either, is appropriate.

How is Mounjaro different from Ozempic under Manitoba Pharmacare?

Ozempic (semaglutide) has published Manitoba EDS criteria for type 2 diabetes after dual therapy with metformin and a sulfonylurea, and still runs through traditional Pharmacare deductible rules rather than no-cost MEPP. Mounjaro has no equivalent published EDS entry. Do not assume the Ozempic EDS pathway transfers to tirzepatide. See our Ozempic Manitoba Pharmacare EDS guide for that process.

Can Manitoba telehealth prescribe Mounjaro or Zepbound?

Licensed clinicians serving Manitoba — in person or via telehealth — may assess whether a Health Canada–authorized tirzepatide product is appropriate and help with private-plan paperwork. A prescription and coverage approval are never guaranteed, and individual results vary. Compare Manitoba-serving clinics in our provider directory and treat outbound clinic links as possibly affiliate.

Sources (re-check before you act)

• Manitoba Drug Benefits and Interchangeability Formulary (formulary effective October 1, 2026 — no tirzepatide listing found 2026-10-12)
• Manitoba Drug Benefits Formulary (PDF)
• Manitoba Exception Drug Status (EDS) notice (PDF) — Ozempic / semaglutide criteria present; tirzepatide absent as of review date
• Manitoba Pharmacare Program
• Pharmacare information for health professionals (EDS forms)
• Health Canada Drug Product Database (search Mounjaro / Zepbound)
• Health Canada — Summary Basis of Decision, Mounjaro
• Zepbound Canadian product monograph (PDF)
• CDA-AMC reimbursement recommendation — tirzepatide (Mounjaro), 2026
• CDA-AMC reimbursement recommendation — tirzepatide (Zepbound), 2026
• pCPA — brand-name drug negotiations
• Lilly Canada — Mounjaro · Lilly Canada — Zepbound

Prairie twins: Mounjaro cost in Alberta · Mounjaro cost in Saskatchewan · Ozempic Manitoba Pharmacare EDS · Semaglutide vs tirzepatide.

Manitoba GLP-1 access → Compare Manitoba-serving providers

Informational eligibility quiz Felix details May be affiliate Maple details May be affiliate